About Windtree Therapeutics (NASDAQ:WINT)
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:WINT
- CUSIP: 25466840
- Web: www.windtreetx.com/
- Market Cap: $2.59 million
- Outstanding Shares: 13,994,000
- 50 Day Moving Avg: $0.21
- 200 Day Moving Avg: $0.75
- 52 Week Range: $0.18 - $3.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.56
- P/E Growth: 0.000
- Annual Revenue: $3.23 million
- Price / Sales: 0.80
- Book Value: ($3.05) per share
- Price / Book: -0.06
- EBITDA: ($28,340,000.00)
- Net Margins: -588.67%
- Return on Assets: -308.95%
- Debt-to-Equity Ratio: -1.09%
- Current Ratio: 0.97%
- Quick Ratio: 0.97%
- Average Volume: 260,729 shs.
- Beta: 1.98
- Short Ratio: 2.46
Frequently Asked Questions for Windtree Therapeutics (NASDAQ:WINT)
What is Windtree Therapeutics' stock symbol?
Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."
How were Windtree Therapeutics' earnings last quarter?
Windtree Therapeutics Inc (NASDAQ:WINT) issued its earnings results on Monday, August, 21st. The company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.99) by $0.23. The firm earned $1.15 million during the quarter, compared to analysts' expectations of $0.40 million. View Windtree Therapeutics' Earnings History.
Where is Windtree Therapeutics' stock going? Where will Windtree Therapeutics' stock price be in 2017?
2 brokerages have issued 1-year price objectives for Windtree Therapeutics' stock. Their predictions range from $8.00 to $8.00. On average, they expect Windtree Therapeutics' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Windtree Therapeutics.
Who are some of Windtree Therapeutics' key competitors?
Some companies that are related to Windtree Therapeutics include Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Humanigen (KBIO), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), LipoScience (LPDX), Mast Therapeutics (MSTX), Oncolytics Biotech (ONCY), Onyx Pharmaceuticals (ONXX), Sirtex Medical Limited (SRX), Tetralogic Pharmaceuticals Corp (TLOG) and Trius Therapeutics (TSRX).
Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the folowing people:
- John R. Leone, Independent Chairman of the Board
- Craig Fraser, President, Chief Executive Officer, Director
- John A. Tattory, Chief Financial Officer, Senior Vice President
- Mary B. Templeton Esq., Senior Vice President, General Counsel and Corporate Secretary
- Kathryn A. Cole, Senior Vice President - Human Resources
- Steven G. Simonson M.D., Senior Vice President and Chief Development Officer
- William C. Roberts, Vice President - Investor Relations and Corporate Communications
- Michael L. Magee, Vice President - Technical Operations
- Mahady M. Joseph, Independent Director
- Bruce A. Peacock, Independent Director
How do I buy Windtree Therapeutics stock?
Shares of Windtree Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Windtree Therapeutics' stock price today?
MarketBeat Community Rating for Windtree Therapeutics (NASDAQ WINT)MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Windtree Therapeutics stock can currently be purchased for approximately $0.19.
Consensus Ratings for Windtree Therapeutics (NASDAQ:WINT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$8.00 (4,224.32% upside)|Consensus Price Target History for Windtree Therapeutics (NASDAQ:WINT)
Analysts' Ratings History for Windtree Therapeutics (NASDAQ:WINT)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/30/2017||Stifel Nicolaus||Downgrade||Buy -> Hold||High|
|10/30/2016||HC Wainwright||Set Price Target||Buy||$8.00||N/A|
Earnings History for Windtree Therapeutics (NASDAQ:WINT)Earnings History by Quarter for Windtree Therapeutics (NASDAQ WINT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/21/2017||Q2 2017||($0.99)||($0.76)||$0.40 million||$1.15 million||View||N/A|
|5/15/2017||Q1 2017||($1.37)||$0.22 million||View||N/A|
|8/10/2016||Q2||($1.64)||($1.29)||$0.08 million||$0.11 million||View||N/A|
|3/24/2016||Q4||($0.70)||($1.26)||$0.07 million||$0.66 million||View||Listen|
|8/10/2015||Q215||($0.13)||($0.13)||$0.45 million||$0.08 million||View||Listen|
|3/16/2015||Q414||($0.14)||($0.12)||$0.54 million||$1.18 million||View||N/A|
|11/6/2014||($0.15)||($0.13)||$0.50 million||$0.53 million||View||N/A|
|8/5/2014||Q2 14||($0.15)||($0.12)||$0.26 million||$1.09 million||View||N/A|
|5/8/2014||Q114||($0.13)||($0.14)||$2.69 million||$0.03 million||View||N/A|
|3/13/2014||Q413||($0.16)||($0.16)||$0.36 million||$0.07 million||View||N/A|
|8/8/2013||Q2 2013||($0.28)||($0.18)||$10.00 million||$0.18 million||View||N/A|
Earnings Estimates for Windtree Therapeutics (NASDAQ:WINT)
Current Year EPS Consensus Estimate: $-2.460 EPS
Next Year EPS Consensus Estimate: $-0.330 EPS
Dividend History for Windtree Therapeutics (NASDAQ:WINT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Windtree Therapeutics (NASDAQ:WINT)
Insider Ownership Percentage: 1.30%Insider Trades by Quarter for Windtree Therapeutics (NASDAQ:WINT)
Institutional Ownership Percentage: 36.81%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/28/2016||Craig Fraser||Insider||Buy||7,500||$2.05||$15,375.00|| |
|2/19/2013||John R Leone||Director||Buy||3,000||$2.88||$8,640.00|| |
Headline Trends for Windtree Therapeutics (NASDAQ:WINT)
Latest Headlines for Windtree Therapeutics (NASDAQ:WINT)
Loading headlines, please wait.
Windtree Therapeutics (WINT) Chart for Monday, October, 23, 2017